{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T23:19:43Z","timestamp":1790983183057,"version":"4.1.0"},"reference-count":8,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,16]]},"DOI":"10.7759\/cureus.112768","type":"journal-article","created":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T10:24:33Z","timestamp":1784197473000},"source":"Crossref","is-referenced-by-count":1,"title":["Haemophagocytic Lymphohistiocytosis Following Ipilimumab and Nivolumab in Malignant Pleural Mesothelioma: A Case Report"],"prefix":"10.7759","author":[{"given":"Cho May","family":"Than","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maung","family":"Moe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye","family":"Win","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyaw","family":"Maung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.21039","article-title":"HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis","volume":"48","author":"Henter JI","year":"2007","unstructured":"Henter JI, Horne A, Aric\u00f3 M, et al.. HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2007, 48:124-31. 10.1002\/pbc.21039","journal-title":"Pediatr Blood Cancer"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32714-8","article-title":"First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial","volume":"397","author":"Baas P","year":"2021","unstructured":"Baas P, Scherpereel A, Nowak AK, et al.. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial.  Lancet. 2021, 397:375-86. 10.1016\/S0140-6736(20)32714-8","journal-title":"Lancet"},{"key":"ref3","unstructured":"FDA approves nivolumab and ipilimumab for unresectable malignant pleural mesothelioma. (2020). https.\/\/www.asco.org\/practice-policy\/policy-issues-statements\/asco-in-action\/fda-approves-nivolumab-and-ipilimumab."},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-018-0365-3","article-title":"Hemophagocytic lymphohistiocytosis with immunotherapy: brief review and case report","volume":"6","author":"Sadaat M","year":"2018","unstructured":"Sadaat M, Jang S. Hemophagocytic lymphohistiocytosis with immunotherapy: brief review and case report. J Immunother Cancer. 2018, 6:49. 10.1186\/s40425-018-0365-3","journal-title":"J Immunother Cancer"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2023-0140","article-title":"Immune checkpoint inhibitor-associated hemophagocytic lymphohistiocytosis in a patient with chronic lymphocytic leukemia","volume":"15","author":"Ali SB","year":"2023","unstructured":"Ali SB, Kuss B, Karapetis C, Hughes T, Smith A. Immune checkpoint inhibitor-associated hemophagocytic lymphohistiocytosis in a patient with chronic lymphocytic leukemia. Immunotherapy. 2023, 15:1531-7. 10.2217\/imt-2023-0140","journal-title":"Immunotherapy"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1080\/16078454.2024.2340144","article-title":"Clinical characterization of hemophagocytic lymphohistiocytosis caused by immune checkpoint inhibitors: a review of published cases","volume":"29","author":"Xu Z","year":"2024","unstructured":"Xu Z, Li H, Yu X, Luo J, Zhang Z. Clinical characterization of hemophagocytic lymphohistiocytosis caused by immune checkpoint inhibitors: a review of published cases. Hematology. 2024, 29:2340144. 10.1080\/16078454.2024.2340144","journal-title":"Hematology"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider BJ","year":"2021","unstructured":"Schneider BJ, Naidoo J, Santomasso BD, et al.. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J Clin Oncol. 2021, 39:4073-126. 10.1200\/JCO.21.01440","journal-title":"J Clin Oncol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12051985","article-title":"Hemophagocytic lymphohistiocytosis associated with immunological checkpoint inhibitors: a pharmacovigilance study","volume":"12","author":"Diaz L","year":"2023","unstructured":"Diaz L, Jauzelon B, Dillies AC, Le Souder C, Faillie JL, Maria AT, Palassin P. Hemophagocytic lymphohistiocytosis associated with immunological checkpoint inhibitors: a pharmacovigilance study. J Clin Med. 2023, 12:1985. 10.3390\/jcm12051985","journal-title":"J Clin Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/512636-haemophagocytic-lymphohistiocytosis-following-ipilimumab-and-nivolumab-in-malignant-pleural-mesothelioma-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T10:24:34Z","timestamp":1784197474000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/512636-haemophagocytic-lymphohistiocytosis-following-ipilimumab-and-nivolumab-in-malignant-pleural-mesothelioma-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,16]]},"references-count":8,"URL":"https:\/\/doi.org\/10.7759\/cureus.112768","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7,16]]}}}